Literature DB >> 28204834

[Pulmonary embolism].

M Hecker1, N Sommer2, A Hecker3, D Bandorski4, M A Weigand5, G A Krombach6, E Mayer7, D Walmrath2.   

Abstract

Pulmonary embolism is a potentially fatal disorder and frequently seen in critical care and emergency medicine. Due to a high mortality rate within the first few hours, the accurate initiation of rational diagnostic pathways in patients with suspected pulmonary embolism and timely consecutive treatment is essential. In this review, the current European guidelines on the diagnosis and therapy of acute pulmonary embolism are presented. Special focus is put on a structured patient management based on the individual risk of early mortality. In particular risk assessment and new risk-adjusted treatment recommendations are presented and discussed in this article.

Entities:  

Keywords:  D-dimer; Lung diseases; Probability; Risk factors; Therapeutic thrombolysis

Mesh:

Year:  2017        PMID: 28204834     DOI: 10.1007/s00101-017-0282-8

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  40 in total

1.  A red blood cell agglutination D-dimer test to exclude deep venous thrombosis in pregnancy.

Authors:  Wee-Shian Chan; Sanjeev Chunilal; Agnes Lee; Mark Crowther; Marc Rodger; Jeffrey S Ginsberg
Journal:  Ann Intern Med       Date:  2007-08-07       Impact factor: 25.391

2.  Aspirin for preventing the recurrence of venous thromboembolism.

Authors:  Cecilia Becattini; Giancarlo Agnelli; Alessandro Schenone; Sabine Eichinger; Eugenio Bucherini; Mauro Silingardi; Marina Bianchi; Marco Moia; Walter Ageno; Maria Rita Vandelli; Elvira Grandone; Paolo Prandoni
Journal:  N Engl J Med       Date:  2012-05-24       Impact factor: 91.245

3.  Management of unsuccessful thrombolysis in acute massive pulmonary embolism.

Authors:  Nicolas Meneveau; Marie-France Séronde; Marie-Cécile Blonde; Pierre Legalery; Katy Didier-Petit; Florent Briand; Fiona Caulfield; François Schiele; Yvette Bernard; Jean-Pierre Bassand
Journal:  Chest       Date:  2006-04       Impact factor: 9.410

4.  Idarucizumab for Dabigatran Reversal.

Authors:  Charles V Pollack; Paul A Reilly; John Eikelboom; Stephan Glund; Peter Verhamme; Richard A Bernstein; Robert Dubiel; Menno V Huisman; Elaine M Hylek; Pieter W Kamphuisen; Jörg Kreuzer; Jerrold H Levy; Frank W Sellke; Joachim Stangier; Thorsten Steiner; Bushi Wang; Chak-Wah Kam; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2015-06-22       Impact factor: 91.245

5.  Derivation and validation of a prognostic model for pulmonary embolism.

Authors:  Drahomir Aujesky; D Scott Obrosky; Roslyn A Stone; Thomas E Auble; Arnaud Perrier; Jacques Cornuz; Pierre-Marie Roy; Michael J Fine
Journal:  Am J Respir Crit Care Med       Date:  2005-07-14       Impact factor: 21.405

6.  Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies.

Authors:  J Lepercq; J Conard; A Borel-Derlon; J Y Darmon; O Boudignat; C Francoual; P Priollet; C Cohen; N Yvelin; J F Schved; M Tournaire; J Y Borg
Journal:  BJOG       Date:  2001-11       Impact factor: 6.531

7.  Maternal mortality in Australia, 1973-1996.

Authors:  Elizabeth A Sullivan; Jane B Ford; Georgina Chambers; Emma K Slaytor
Journal:  Aust N Z J Obstet Gynaecol       Date:  2004-10       Impact factor: 2.100

8.  Dabigatran versus warfarin in the treatment of acute venous thromboembolism.

Authors:  Sam Schulman; Clive Kearon; Ajay K Kakkar; Patrick Mismetti; Sebastian Schellong; Henry Eriksson; David Baanstra; Janet Schnee; Samuel Z Goldhaber
Journal:  N Engl J Med       Date:  2009-12-10       Impact factor: 91.245

Review 9.  Ultrasound-assisted thrombolysis for acute pulmonary embolism: a systematic review.

Authors:  Rolf P Engelberger; Nils Kucher
Journal:  Eur Heart J       Date:  2014-02-03       Impact factor: 29.983

10.  Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study.

Authors:  E R Pomp; A M Lenselink; F R Rosendaal; C J M Doggen
Journal:  J Thromb Haemost       Date:  2008-01-31       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.